This article was downloaded by: [Selcuk Universitesi] On: 31 January 2015, At: 10:51 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Human Vaccines & Immunotherapeutics Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/khvi20
Letter from the Editor a
Ronald Ellis & Eva M Riedmann a
Chief Technology Officer; FutuRx, Ltd.; Ness Ziona, Israel
Acquisitions Editor; Landes Bioscience; Vienna, Austria Published online: 16 Apr 2014.
Click for updates To cite this article: Ronald Ellis & Eva M Riedmann (2014) Letter from the Editor, Human Vaccines & Immunotherapeutics, 10:2, 245-246, DOI: 10.4161/hv.28445 To link to this article: http://dx.doi.org/10.4161/hv.28445
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.
Human Vaccines & Immunotherapeutics 10:2, 245–245; February 2014; © 2014 Landes Bioscience
Letter from the Editor Ronald Ellis1,* and Eva M Riedmann2 Chief Technology Officer; FutuRx, Ltd.; Ness Ziona, Israel; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria
Downloaded by [Selcuk Universitesi] at 10:51 31 January 2015
In the current issue, we are pleased to present multiple papers on Licensed Vaccines: a review on Japanese encephalitis vaccines (Yun, p. 263), a clinical study on the immunogenicity and safety of CRM-conjugated meningococcal ACWY vaccine (Nolan, p. 280), impact on vaccine efficacy of mismatches in T-cell and B-cell epitopes of the mumps vaccine strain (Homan, p. 290), motor palsies of cranial nerves after vaccination (Woo, p. 301), as well as two commentaries on adult immunization (Mehta, p. 306) and routine vaccination against MenB (Kaaijk, p. 310). Finally, this section features a letter discussing a recent publication in HV&I related to the safety of the purified chick embryo cell rabies vaccine Vaxirab N (Gozdas, p. 317), as well as a reply letter by the authors of the initial study (Ravish, p. 319). A number of contributions are related to Immunotherapy, including a review on polymeric nanoparticles for vaccine delivery (Bolhassani, p. 321), and studies on biological containment of live Lactococcus lactis-based delivery vectors (Hanin, p. 333), clinical response of ovarian clear cell carcinoma to a novel peptide vaccine therapy (Suzuki, p. 338), toxin neutralization by anti-tetanus toxin monoclonal antibodies (Yousefi, p. 344), immunotherapy for non-small-cell lung cancer (Suzuki, p. 352), and finally a case report on administration of immunoglobulin in the course of Henoch-Schönlein purpura in a patient with familiar prostatic adenocarcinoma (Sobieszczańska, p. 358). The section Novel Vaccines features articles on epidemiology, diagnosis and vaccines for coxsackievirus A16 (Mao, p. 360), use of an avirulent Yersinia pestis strain to protect monkeys against bubonic plague (Zhang, p. 368), a novel tuberculosis vaccine p846 that elicits robust immune responses and alleviates lung injury (Kong, p. 378), comparison of BCG prime-DNA booster and recombinant BCG regimens for protection against tuberculosis (Tan, p. 391), a novel schistosomiasis vaccine based on the lipid core peptide system and the antigen cathepsin D hemoglobinase of Schistosoma mansoni (Dougall, p. 399), and TLR-7 and 9 agonists as mucosal adjuvants for norovirus virus-like particle vaccines (Hjelm, p. 410). In this section you can also find two commentaries discussing the importance of effective vaccines against hepatitis C (Mehta, p. 417), and tuberculosis (Chawla, p. 420). Several studies deal with different aspects of Influenza: effectiveness of influenza vaccines at preventing hospitalization due to acute exacerbation of cardiopulmonary disease (Seo, p. 423), medical and economic burden of influenza in the elderly population (Kovács, p. 428), immunogenicity and safety of an inactivated trivalent cell culture-derived vaccine (Vinnemeier, p. 441), coverage and predictors of vaccination against 2012/13 seasonal influenza in Spain (Jiménez-García, p. 449), adult preferences for influenza vaccines with lower likelihood of side effects (Effler, p. 456), and the small molecule Nizatidine as enhancer of cell-mediated responses to a H5N1 vaccine in mice (Wang, p. 461). A paper related to HPV looks at the clinical safety of an Escherichia coli-expressed bivalent HPV virus-like particle vaccine (Hu, p. 469). Two articles fall in the category Acceptance: vaccination coverage among children in Germany estimated by analysis of health insurance claims data (Rieck, p. 476), and experiences in recruiting volunteers through community-based initiatives in Phase 1 vaccine trials in India (Sahay, p. 485). Economic evaluation of adult immunization with 13-valent pneumococcal vaccine is the topic of a study in our Pneumococcal section (Liguori, p. 492). In the categories Hepatitis, Rotavirus and HIV, we present papers on the effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children (Chen, p. 498), analysis of clinical trials to study the association of serum anti-rotavirus
*Correspondence to: Ronald Ellis; Email: [email protected]
Submitted: 1/12/2014; Accepted: 1/12/2014; Published Online: 04/16/2014 http://dx.doi.org/10.4161/hv.28445
Human Vaccines & Immunotherapeutics 245
IgA seropositivity and protection against severe rotavirus gastroenteritis (Cheuvart, p. 505), and host genomic HIV restriction factors modulating the response to dendritic cell-based treatment against HIV-1 (Pontillo, p. 512). A meeting report from the Canadian Adjuvant Initiative Workshop 2013 (Krishnan, p. 519) in the section Technologies rounds out his issue. As always, our monthly News, Policy & Profiles (NP&P) track features a selection of the latest news in the field of vaccines and immunotherapeutics. This section is also an excellent platform to share your opinion on timely, interesting and controversial topics in your field. The current issue features a Commentary by Dr Anne De Groot (p. 256) discussing the low immunogenicity of H7N9 influenza virus and subsequent challenges for vaccine design. If you wish to share your opinion with HV&I readers, contact the Acquisitions Editor Eva Riedmann ([email protected]
) with your ideas for commentaries and opinion pieces. We thank all peer-reviewers for their reviews during 2013, who are listed in this issue. This issue also features our recognition of the Peer Reviewer of the Year, Dr Mark Newman (p. 247).
Downloaded by [Selcuk Universitesi] at 10:51 31 January 2015
Last but not least, we want to draw your attention to several popular web site features, which are usuable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a HV&I facebook account for daily updates. Sincerely, Ronald Ellis, PhD Editor-in-Chief Eva M Riedmann, PhD Acquisitions Editor
Human Vaccines & Immunotherapeutics
Volume 10 Issue 2